SG10201906460PA - Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region - Google Patents
Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant RegionInfo
- Publication number
- SG10201906460PA SG10201906460PA SG10201906460PA SG10201906460PA SG10201906460PA SG 10201906460P A SG10201906460P A SG 10201906460PA SG 10201906460P A SG10201906460P A SG 10201906460PA SG 10201906460P A SG10201906460P A SG 10201906460PA SG 10201906460P A SG10201906460P A SG 10201906460PA
- Authority
- SG
- Singapore
- Prior art keywords
- car
- constant region
- receptor
- beta constant
- binding domains
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 6
- 239000000427 antigen Substances 0.000 title abstract 3
- 102000036639 antigens Human genes 0.000 title abstract 3
- 108091007433 antigens Proteins 0.000 title abstract 3
- 108091008874 T cell receptors Proteins 0.000 title abstract 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 abstract 2
- 101000662902 Homo sapiens T cell receptor beta constant 2 Proteins 0.000 abstract 1
- 102100037298 T cell receptor beta constant 2 Human genes 0.000 abstract 1
- 206010042971 T-cell lymphoma Diseases 0.000 abstract 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/464838—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/7051—T-cell receptor (TcR)-CD3 complex
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
Abstract
CHIMERIC ANTIGEN RECEPTOR (CAR) WITH ANTIGEN BINDING DOMAINS TO THE T CELL RECEPTOR BETA CONSTANT REGION The present disclosure relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or 5 TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject. No Figure to Accompany
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201403905A GB201403905D0 (en) | 2014-03-05 | 2014-03-05 | Method |
| GB201416908A GB201416908D0 (en) | 2014-09-25 | 2014-09-25 | Method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201906460PA true SG10201906460PA (en) | 2019-09-27 |
Family
ID=52649058
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906460PA SG10201906460PA (en) | 2014-03-05 | 2015-03-05 | Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region |
| SG10201906461SA SG10201906461SA (en) | 2014-03-05 | 2015-03-05 | Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region |
| SG11201606583VA SG11201606583VA (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201906461SA SG10201906461SA (en) | 2014-03-05 | 2015-03-05 | Chimeric Antigen Receptor (Car) With Antigen Binding Domains to the T Cell Receptor Beta Constant Region |
| SG11201606583VA SG11201606583VA (en) | 2014-03-05 | 2015-03-05 | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20170066827A1 (en) |
| EP (2) | EP3125934B1 (en) |
| JP (5) | JP6767872B2 (en) |
| KR (3) | KR102088082B1 (en) |
| CN (3) | CN106068276B (en) |
| AU (3) | AU2015225944B2 (en) |
| BR (1) | BR112016020304B1 (en) |
| CA (1) | CA2940564C (en) |
| CL (4) | CL2016002195A1 (en) |
| CU (1) | CU24475B1 (en) |
| DK (1) | DK3125934T3 (en) |
| ES (1) | ES2758173T3 (en) |
| HU (1) | HUE047641T2 (en) |
| IL (3) | IL278878B (en) |
| MX (3) | MX2016010856A (en) |
| MY (1) | MY173567A (en) |
| PE (2) | PE20211887A1 (en) |
| PH (2) | PH12016501646A1 (en) |
| PL (1) | PL3125934T3 (en) |
| PT (1) | PT3125934T (en) |
| RU (3) | RU2018140694A (en) |
| SG (3) | SG10201906460PA (en) |
| WO (1) | WO2015132598A1 (en) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11885807B2 (en) | 2014-03-05 | 2024-01-30 | Autolus Limited | Method for depleting malignant T-cells |
| US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
| GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
| WO2016051205A1 (en) * | 2014-10-03 | 2016-04-07 | Isis Innovation Limited | Analysis of t-cell monotypia |
| CA2937157A1 (en) * | 2016-07-25 | 2018-01-25 | Ucl Business Plc | Protein-based t-cell receptor knockdown |
| SG11201907299XA (en) | 2017-02-08 | 2019-09-27 | Dragonfly Therapeutics Inc | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
| ES2955074T3 (en) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteins that bind to HER2, NKG2D and CD16 |
| CA3053358A1 (en) * | 2017-04-04 | 2018-10-11 | F. Hoffmann-La Roche Ag | Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap |
| GB201709203D0 (en) * | 2017-06-09 | 2017-07-26 | Autolus Ltd | Antigen-binding domain |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| IL311488A (en) * | 2017-08-23 | 2024-05-01 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| WO2019129850A1 (en) * | 2017-12-29 | 2019-07-04 | Cellectis | Off-the-shelf engineered cells for therapy |
| JP7372920B2 (en) * | 2017-12-29 | 2023-11-01 | セレクティス | Methods for improving the generation of CAR T cells |
| GB201800298D0 (en) * | 2018-01-09 | 2018-02-21 | Autolus Ltd | Method |
| US20200339687A1 (en) * | 2018-01-19 | 2020-10-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for targeting gamma delta t cells with chimeric antigen receptors |
| WO2019157366A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the nkg2d receptor |
| US20210283180A1 (en) * | 2018-07-06 | 2021-09-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Car t cell therapy to target t cell specific cancers |
| WO2020018708A1 (en) * | 2018-07-18 | 2020-01-23 | The General Hospital Corporation | Compositions and methods for treatment of t cell malignancies |
| GB201812650D0 (en) | 2018-08-03 | 2018-09-19 | Autolus Ltd | Molecular assessment of TRBC usage |
| GB201817172D0 (en) | 2018-10-22 | 2018-12-05 | Autolus Ltd | Antibody |
| US20220041718A1 (en) * | 2018-10-31 | 2022-02-10 | Autolus Limited | Binding domain |
| EP3919515A4 (en) * | 2019-01-29 | 2022-11-23 | Shanghai Jiao Tong University | Chimeric antigen receptor and use thereof |
| EP3927744A1 (en) * | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to t cell related cancer cells and uses thereof |
| CN110317266A (en) * | 2019-07-17 | 2019-10-11 | 东北农业大学 | Three kinds of scFv antibody, its encoding gene and its application in the O-shaped hoof-and-mouth disease preparation of preparation treatment or prevention |
| EP4121518A4 (en) * | 2020-03-16 | 2024-06-19 | Marengo Therapeutics, Inc. | Engineered cell compositions and methods of use thereof |
| GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| WO2021205175A1 (en) | 2020-04-09 | 2021-10-14 | Autolus Limited | Molecule |
| GB202101491D0 (en) | 2021-02-03 | 2021-03-17 | Autolus Ltd | Molecule |
| JP2023523011A (en) * | 2020-04-24 | 2023-06-01 | マレンゴ・セラピューティクス，インコーポレーテッド | Multifunctional molecules that bind to T cell-associated cancer cells and uses thereof |
| CN111537735A (en) * | 2020-05-15 | 2020-08-14 | 江西赛基生物技术有限公司 | Antibody detection kit and application thereof in immunoassay |
| CN111549044B (en) * | 2020-07-13 | 2020-10-23 | 北京市肿瘤防治研究所 | Preparation method and application of targeted TRBC1 CAR-T cell |
| WO2022038115A1 (en) * | 2020-08-18 | 2022-02-24 | Medigene Immunotherapies Gmbh | ENRICHMENT OF T CELLS USING AN ANTI-Cß ANTIBODY |
| AU2021333779A1 (en) * | 2020-08-26 | 2023-04-13 | Marengo Therapeutics, Inc. | Methods of detecting TRBC1 or TRBC2 |
| AU2022222679A1 (en) | 2021-02-17 | 2023-09-07 | The Johns Hopkins University | Methods and materials for treating clonal t cell expansions |
| WO2022177870A1 (en) * | 2021-02-17 | 2022-08-25 | The Board Of Regents Of The University Of Texas System | Multimeric sars-cov-2 binding molecules and uses thereof |
| GB202112923D0 (en) * | 2021-09-10 | 2021-10-27 | Ucl Business Ltd | Binding domain |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06502529A (en) * | 1990-08-09 | 1994-03-24 | ナショナル ジューイッシュ センター フォア イミュノロジィ アンド レスパラトリィ メディスン | Method for producing monoclonal antibodies against human T cell receptor elements using recombinant DNA vectors |
| US6790604B1 (en) * | 1998-05-12 | 2004-09-14 | Stefan A. Cohen | Methods for identifying or diagnosing carcinoma cells with metastatic potential based on the measurement of lymphoid genes or their products in carcinoma cells |
| WO2003093318A1 (en) * | 2002-04-29 | 2003-11-13 | Genpat77 Pharmacogenetics Ag | Novel antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| RU2355703C2 (en) * | 2002-10-09 | 2009-05-20 | Медиджен Лимитед | Single-strand recombinant t-cell receptors |
| GB0304068D0 (en) * | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| US7741045B2 (en) * | 2006-11-16 | 2010-06-22 | General Electric Company | Sequential analysis of biological samples |
| WO2009151628A2 (en) * | 2008-06-12 | 2009-12-17 | Gov't Of The Usa, As Represented By The Secretary, Department Of Health Human Services | Monitoring tcr-b to determine hiv therapy and disease progression |
| CA2735193A1 (en) * | 2008-08-26 | 2010-03-11 | Macrogenics, Inc. | T-cell receptor antibodies and methods of use thereof |
| ME02505B (en) * | 2009-12-29 | 2017-02-20 | Aptevo Res & Development Llc | Heterodimer binding proteins and uses thereof |
| JP6000507B2 (en) * | 2010-09-30 | 2016-09-28 | パナソニックヘルスケアホールディングス株式会社 | Medical information registration device |
| BR122021026169B1 (en) * | 2010-12-09 | 2023-12-12 | The Trustees Of The University Of Pennsylvania | USE OF A CELL |
| WO2013074916A1 (en) * | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| WO2013176916A1 (en) * | 2012-05-25 | 2013-11-28 | Roman Galetto | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
| US10443100B2 (en) * | 2014-05-22 | 2019-10-15 | The Scripps Research Institute | Gene expression profiles associated with sub-clinical kidney transplant rejection |
| BR112017005245A2 (en) * | 2014-09-19 | 2017-12-12 | Regeneron Pharma | genetically modified nonhuman animal, methods for producing t cell, t cell hybridoma, nucleic acid, specific antibody, human cell, genetically modified nonhuman animal and for inducing an immune response, cell, t cell hybridoma, acid nucleic acid, specific antibody, chimeric antigen receptor, non-human embryo, chimeric antigen receptor locus, and nucleic acid composition. |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | Harvard College | modified t-cells and methods of producing and using them |
-
2015
- 2015-03-05 CN CN201580011306.XA patent/CN106068276B/en active Active
- 2015-03-05 EP EP15709319.6A patent/EP3125934B1/en active Active
- 2015-03-05 KR KR1020167027423A patent/KR102088082B1/en active IP Right Grant
- 2015-03-05 PE PE2021000759A patent/PE20211887A1/en unknown
- 2015-03-05 BR BR112016020304-6A patent/BR112016020304B1/en active IP Right Grant
- 2015-03-05 RU RU2018140694A patent/RU2018140694A/en unknown
- 2015-03-05 CN CN202010859460.5A patent/CN112094353A/en active Pending
- 2015-03-05 WO PCT/GB2015/050643 patent/WO2015132598A1/en active Application Filing
- 2015-03-05 IL IL278878A patent/IL278878B/en unknown
- 2015-03-05 MY MYPI2016703188A patent/MY173567A/en unknown
- 2015-03-05 RU RU2021101502A patent/RU2021101502A/en unknown
- 2015-03-05 US US15/123,287 patent/US20170066827A1/en not_active Abandoned
- 2015-03-05 PL PL15709319T patent/PL3125934T3/en unknown
- 2015-03-05 EP EP17172755.5A patent/EP3241561A1/en active Pending
- 2015-03-05 CN CN202010858243.4A patent/CN112094347A/en active Pending
- 2015-03-05 PE PE2016001548A patent/PE20170125A1/en unknown
- 2015-03-05 KR KR1020207006445A patent/KR102235202B1/en active IP Right Grant
- 2015-03-05 DK DK15709319.6T patent/DK3125934T3/en active
- 2015-03-05 SG SG10201906460PA patent/SG10201906460PA/en unknown
- 2015-03-05 JP JP2016554603A patent/JP6767872B2/en active Active
- 2015-03-05 SG SG10201906461SA patent/SG10201906461SA/en unknown
- 2015-03-05 MX MX2016010856A patent/MX2016010856A/en active IP Right Grant
- 2015-03-05 CA CA2940564A patent/CA2940564C/en active Active
- 2015-03-05 HU HUE15709319A patent/HUE047641T2/en unknown
- 2015-03-05 CU CU2016000129A patent/CU24475B1/en unknown
- 2015-03-05 RU RU2016138421A patent/RU2744046C2/en active
- 2015-03-05 PT PT157093196T patent/PT3125934T/en unknown
- 2015-03-05 SG SG11201606583VA patent/SG11201606583VA/en unknown
- 2015-03-05 KR KR1020207006444A patent/KR102235201B1/en active IP Right Grant
- 2015-03-05 ES ES15709319T patent/ES2758173T3/en active Active
- 2015-03-05 AU AU2015225944A patent/AU2015225944B2/en active Active
-
2016
- 2016-08-04 IL IL247110A patent/IL247110A0/en active IP Right Grant
- 2016-08-17 PH PH12016501646A patent/PH12016501646A1/en unknown
- 2016-08-19 MX MX2019013846A patent/MX2019013846A/en unknown
- 2016-08-19 MX MX2019013845A patent/MX2019013845A/en unknown
- 2016-09-01 CL CL2016002195A patent/CL2016002195A1/en unknown
-
2017
- 2017-05-26 US US15/606,480 patent/US20170334998A1/en not_active Abandoned
- 2017-05-31 JP JP2017107689A patent/JP6767931B2/en active Active
-
2018
- 2018-10-30 CL CL2018003096A patent/CL2018003096A1/en unknown
-
2019
- 2019-06-07 CL CL2019001567A patent/CL2019001567A1/en unknown
- 2019-06-07 CL CL2019001568A patent/CL2019001568A1/en unknown
- 2019-07-09 AU AU2019204925A patent/AU2019204925B2/en active Active
- 2019-07-09 AU AU2019204921A patent/AU2019204921C1/en active Active
-
2020
- 2020-03-25 JP JP2020054667A patent/JP7149304B2/en active Active
- 2020-04-01 PH PH12020550203A patent/PH12020550203A1/en unknown
- 2020-11-22 IL IL278879A patent/IL278879A/en unknown
-
2021
- 2021-09-15 JP JP2021150189A patent/JP2021184773A/en not_active Withdrawn
-
2024
- 2024-04-03 JP JP2024060080A patent/JP2024074907A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020550203A1 (en) | Chimeric antigen receptor (car) with antigen binding domains to the t cell receptor beta constant region | |
| ZA202206078B (en) | Anti-cd3 antibodies and methods of use | |
| MX2022014867A (en) | Antibodies specific to human poliovirus receptor (pvr). | |
| MX2022003995A (en) | Chimeric antigen and t cell receptors and methods of use. | |
| MX2017001008A (en) | Treatment of cancer using a cd33 chimeric antigen receptor. | |
| MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
| MY186016A (en) | Anti-tigit antibodies and methods of use | |
| IL247320A0 (en) | Il-2r beta-selective agonists in combination with an anti ctla-4 antibody or an an anti pd-1 antibodies for treating cancer | |
| MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
| MX2017003640A (en) | Chimeric antigen receptors. | |
| MX2020007021A (en) | Treatment of cancer using humanized anti-cd19 chimeric antigen receptor. | |
| MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
| PH12020500225A1 (en) | Anti- cd137 antibodies | |
| EP3611192A3 (en) | T cell recruiting polypeptides based on tcr alpha/beta reactivity | |
| EP3511422A3 (en) | Methods and compositions for diagnosing, prognosing, and treating endometriosis | |
| MX2020009864A (en) | Anti-cd137 antibodies for combination with anti-pd-1 antibodies. | |
| MX2020009863A (en) | Anti-cd137 antibodies for combination with anti-pd-l1 antibodies. | |
| MY192384A (en) | Anti-cd3 antibodies and methods of use |